Reported Earnings • Apr 09
Full year 2025 earnings released: €0.033 loss per share (vs €0.023 loss in FY 2024) Full year 2025 results: €0.033 loss per share (further deteriorated from €0.023 loss in FY 2024). Revenue: €52.9m (up 2.4% from FY 2024). Net loss: €749.0k (loss widened 43% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. New Risk • Mar 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risk Market cap is less than US$100m (€13.3m market cap, or US$15.4m). Reported Earnings • May 05
Full year 2024 earnings released: €0.023 loss per share (vs €0.024 profit in FY 2023) Full year 2024 results: €0.023 loss per share (down from €0.024 profit in FY 2023). Revenue: €51.7m (up 4.5% from FY 2023). Net loss: €524.0k (down 194% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. New Risk • Apr 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€17.1m market cap, or US$19.2m). Aankondiging • Apr 10
EuKedos S.p.A., Annual General Meeting, Jun 30, 2025 EuKedos S.p.A., Annual General Meeting, Jun 30, 2025, at 11:00 W. Europe Standard Time. New Risk • Feb 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (€18.2m market cap, or US$18.8m). Reported Earnings • Apr 07
Full year 2023 earnings released: EPS: €0.024 (vs €0.019 in FY 2022) Full year 2023 results: EPS: €0.024 (up from €0.019 in FY 2022). Revenue: €49.5m (up 5.1% from FY 2022). Net income: €556.0k (up 26% from FY 2022). Profit margin: 1.1% (up from 0.9% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. New Risk • Oct 05
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.8% net profit margin). Market cap is less than US$100m (€20.5m market cap, or US$21.5m). New Risk • Oct 01
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.8% Last year net profit margin: 1.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Share price has been highly volatile over the past 3 months (7.3% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (0.8% net profit margin). Market cap is less than US$100m (€21.5m market cap, or US$22.7m). New Risk • Sep 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€21.9m market cap, or US$23.3m). New Risk • Sep 10
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€22.7m market cap, or US$24.3m). Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Luca Golfieri was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Sep 30
First half 2022 earnings released: €0.011 loss per share (vs €0.014 loss in 1H 2021) First half 2022 results: €0.011 loss per share (improved from €0.014 loss in 1H 2021). Revenue: €22.5m (up 2.6% from 1H 2021). Net loss: €257.0k (loss narrowed 19% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Pierluigi Rosa was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €1.32, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 23x in the Healthcare industry in Italy. Total returns to shareholders of 32% over the past three years. Reported Earnings • Mar 14
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: EPS: €0.025 (up from €0.084 loss in FY 2020). Revenue: €44.0m (down 6.4% from FY 2020). Net income: €570.0k (up €2.49m from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 163%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 12
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: EPS: €0.025 (up from €0.084 loss in FY 2020). Revenue: €45.2m (down 3.9% from FY 2020). Net income: €570.0k (up €2.49m from FY 2020). Profit margin: 1.3% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 163%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Reported Earnings • Oct 03
First half 2021 earnings released: €0.014 loss per share (vs €0.056 loss in 1H 2020) The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: €21.9m (down 9.4% from 1H 2020). Net loss: €319.0k (loss narrowed 75% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings. Reported Earnings • May 05
Full year 2020 earnings released: €0.084 loss per share (vs €0.023 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: €47.0m (down 12% from FY 2019). Net loss: €1.92m (down 473% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 08
New 90-day high: €1.19 The company is up 43% from its price of €0.83 on 09 October 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 3.0% over the same period. Is New 90 Day High Low • Dec 15
New 90-day high: €1.04 The company is up 25% from its price of €0.83 on 15 September 2020. The Italian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 12% over the same period. Is New 90 Day High Low • Nov 25
New 90-day high: €0.94 The company is up 8.0% from its price of €0.87 on 26 August 2020. The Italian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 22% over the same period. Is New 90 Day High Low • Nov 03
New 90-day high: €0.90 The company is up 10.0% from its price of €0.82 on 05 August 2020. The Italian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 11% over the same period. Reported Earnings • Sep 28
First half earnings released Over the last 12 months the company has reported total losses of €827.0k, with earnings decreasing by €1.35m from the prior year. Total revenue was €51.2m over the last 12 months, down 1.9% from the prior year.